Who this is for: IP teams at innovator and generic companies, portfolio managers running LOE models, R&D leads evaluating lifecycle […]

The Market You’re Actually Competing In The generic drug industry saves the U.S. healthcare system more than $445 billion per

Who This Guide Is For This is not an overview. It is a field manual for IP counsel preparing a

Introduction: Two Systems Built for Different Problems, Forced to Coexist In pharmaceutical patent law, the rules changed permanently on September

The question sounds deceptively simple: should you put a brand name on your generic drug? In practice, it is one

The conventional view of a pharmaceutical patent is simple: it is a monopoly right, a wall built to keep competitors

The pharmaceutical industry has spent much of the past decade performing a kind of collective memory erasure about small molecules.

A reference-grade guide for generic drug IP teams, litigation counsel, portfolio managers, business development executives, and institutional investors who need

How integrating patent, clinical, and scientific data into a single intelligence engine is replacing guesswork in life sciences strategy—and what